Leucettine L41

Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) and CDC-like kinases (CLKs) . Leucettine L41 can also inhibit GSK-3 singnaling. Leucettine L41 can inhibit cell apoptosis and ROS production. Leucettine L41 can promote β-cell cell cycle progression, cell proliferation and increase insulin secretion. Leucettine L41 can be used for the researches of neurological disease and metabolic disease, such as Alzheimer’s disease (AD) and diabetes[1][2].

Product Specifications

CAS Number

[1112978-84-3]

UNSPSC

12352005

Hazard Statement

H319

Target

Apoptosis; CDK; DYRK; GSK-3; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Neuroscience-Neurodegeneration

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/leucettine-l41.html

Purity

98.98

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

O=C1NC(NC2=CC=CC=C2)=N/C1=C\C3=CC=C(OCO4)C4=C3

Molecular Formula

C17H13N3O3

Molecular Weight

307.30

Precautions

H319

References & Citations

[1]Naert G, et al. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice. Eur Neuropsychopharmacol. 2015 Nov;25 (11) :2170-82.|[2]Pucelik B, et al. DYRK1A inhibitors leucettines and TGF-β inhibitor additively stimulate insulin production in beta cells, organoids, and isolated mouse islets. PLoS One. 2023 May 17;18 (5) :e0285208.